We are on a missionto exponentially improve the number of quality years for patients.
We are building upon our leadership team’s proven track record of designing and developing innovative small molecules, that aim to overcome the limitations of existing therapies.
The BlossomHill Way, is our intentional, chemistry-based approach that has yielded multiple clinical-stage programs with the potential to address significant unmet medical needs in cancer treatment.
We are deeply committed to those who matter most: patients.
Join us to help redefine the treatment of cancer by advancing the next generation of targeted therapies.
Latest News
-
June 11, 2026
BlossomHill Therapeutics Presents Initial Clinical Data from Dose Escalation in Ongoing Phase 1/1b Trial of Novel Macrocyclic CLK Inhibitor, BH-30236, in Patients with R/R AML or HR-MDS at EHA 2026
Read More -
May 21, 2026
BlossomHill Therapeutics to Present Preliminary Results From Phase 1 Dose Escalation/Backfill Cohorts in Phase 1/2 SOLARA Trial of OMNI-EGFR Inhibitor, BH-30643, in Advanced EGFR-mutant NSCLC at the 2026 ASCO Annual Meeting
Read More -
May 20, 2026
BlossomHill Therapeutics Expands Board of Directors with the Appointments of Sheila Gujrathi, M.D., and John Schmid
Read More